BioAtla, Inc. Common Stock (BCAB)

Price$4.91

Favorite Metrics

Price vs S&P 500 (26W)-94.12%

Price vs S&P 500 (4W)-49.51%

Market Capitalization$7.46M

All Metrics

Book Value / Share (Quarterly)$0.01

P/TBV (Annual)0.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)100.00%

Cash Flow / Share (Quarterly)$-37.98

Price vs S&P 500 (YTD)-86.77%

Net Profit Margin (TTM)-489.20%

EPS (TTM)$-21.93

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-21.93

Revenue Growth (5Y)-17.40%

EPS (Annual)$-50.66

ROI (Annual)-489.14%

Net Profit Margin (5Y Avg)-10136.95%

Cash / Share (Quarterly)$5.61

ROA (Last FY)-431.06%

Revenue Growth TTM (YoY)-81.82%

EBITD / Share (TTM)$-2.12

ROE (5Y Avg)-157.05%

Operating Margin (TTM)-483.05%

Cash Flow / Share (Annual)$-37.98

P/B Ratio13.65x

P/B Ratio (Quarterly)37.03x

Net Income / Employee (Annual)$-1

Net Interest Coverage (TTM)-11.49x

ROA (TTM)-233.57%

EPS Incl Extra (Annual)$-50.66

Current Ratio (Annual)0.37x

Quick Ratio (Quarterly)0.32x

3-Month Avg Trading Volume0.05M

52-Week Price Return-71.43%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.98

P/S Ratio (Annual)3.73x

Asset Turnover (Annual)0.14x

52-Week High$71.50

Operating Margin (5Y Avg)-10034.24%

EPS Excl Extra (Annual)$-50.66

26-Week Price Return-90.14%

Quick Ratio (Annual)0.32x

13-Week Price Return-71.36%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.37x

Enterprise Value$4.489

Revenue / Share Growth (5Y)60.02%

Asset Turnover (TTM)0.14x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-2980.35%

Cash / Share (Annual)$5.61

3-Month Return Std Dev151.15%

Net Income / Employee (TTM)$-1

ROE (Last FY)-489.14%

Net Interest Coverage (Annual)-15.82x

EPS Basic Excl Extra (Annual)$-50.66

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-21.93

ROI (TTM)-235.89%

P/S Ratio (TTM)3.73x

Pretax Margin (5Y Avg)-10137.22%

Revenue / Share (Annual)$1.70

Tangible BV / Share (Annual)$3.79

Price vs S&P 500 (52W)-101.26%

Year-to-Date Return-84.13%

5-Day Price Return-0.33%

EPS Normalized (Annual)$-50.66

ROA (5Y Avg)-150.40%

Net Profit Margin (Annual)-2980.35%

Month-to-Date Return-44.04%

Cash Flow / Share (TTM)$-2.64

EBITD / Share (Annual)$-51.31

Operating Margin (Annual)-2985.55%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-157.03%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-21.93

P/TBV (Quarterly)0.80x

P/B Ratio (Annual)2.40x

Pretax Margin (TTM)-489.20%

Book Value / Share (Annual)$12.28

Price vs S&P 500 (13W)-72.05%

Beta0.96x

Revenue / Share (TTM)$1.67

ROE (TTM)-235.89%

52-Week Low$3.92

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.29

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
BCABBioAtla, Inc. Common Stock	3.73x	-81.82%	—	—	$4.91
AMGNAmgen Inc	5.13x	9.95%	73.30%	2.93%	$349.39
GILDGilead Sciences Inc	5.84x	2.40%	78.83%	133.64%	$138.55
ARGXargenx SE American Depositary Shares	12.46x	89.56%	150.91%	—	$828.35
BNTXBioNTech SE American Depositary Share	8.75x	-11.81%	84.21%	—	$102.12
BIIBBiogen Inc. Common Stock	2.60x	2.22%	75.69%	-18.77%	$176.02
MRNAModerna, Inc. Common Stock	11.02x	-39.93%	70.32%	—	$54.68
NBIXNeurocrine Biosciences Inc	4.49x	21.45%	98.18%	2.31%	$128.41
EXELExelixis Inc	4.96x	6.85%	96.39%	31.10%	$44.38
TECHBio-Techne Corp.	7.60x	1.64%	66.60%	-20.58%	$57.36
HALOHalozyme Therapeutics, Inc.	5.74x	37.55%	83.62%	22.89%	$66.64

About

BioAtla Inc is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for solid tumor cancers. The company's pipeline includes multiple programs featuring designed antibodies and bispecific antibodies, with lead candidates mecbotamab vedotin, ozuriftamab vedotin, and evalstotug in development, along with a Phase 1 trial for BA3182, a bispecific antibody targeting EpCAM and CD3. Its focus on precision-engineered antibodies aims to address unmet needs in oncology with potentially improved specificity and tolerability compared to conventional approaches.